Sign in Subscribe
Cancer research

Gastric Cancer Research Uncovers Insights into Chemotherapy Regimens

Strategic Insights

— 1 min read

A recent study published in the Journal of Oncological Sciences has provided new insights into the effectiveness of various chemotherapy regimens for treating metastatic gastric cancer. The research, conducted by a team of scientists at Ege University Faculty of Medicine, aimed to evaluate the impact of triplet versus doublet chemotherapy regimens and cisplatin versus oxaliplatin-based therapies on survival and safety in patients with HER2-negative metastatic gastric cancer.

Key Takeaways:

  • The study analyzed data from 259 patients with HER2-negative metastatic gastric cancer treated between 2012 and 2021.
  • The results showed that median progression-free survival (PFS) and overall survival (OS) were not significantly different between triplet and doublet groups (PFS: 6.77 vs. 4.90 months; OS: 11.02 vs. 9.43 months; p 0.05 for both).
  • Multivariate analysis demonstrated that oxaliplatin significantly reduced progression risk without a significant OS benefit.
  • Triplet therapy had no significant impact on PFS or OS, but subgroup analyses revealed OS benefits in patients with poor differentiation/signet-ring cell histology, lymph node metastasis, or peritoneal metastasis.
  • Oxaliplatin-based therapy particularly benefited patients aged 65 years with comorbidities, middle gastric tumours, or 2 metastatic sites.

Statistics:

  • 259 patients with HER2-negative metastatic gastric cancer were included in the study.
  • 188 patients received triplet chemotherapy regimens and 71 received doublet regimens.
  • 59 patients received oxaliplatin-based therapy and 203 received cisplatin-based therapy.
  • Median PFS was 6.77 months in the triplet group and 4.90 months in the doublet group.
  • Median OS was 11.02 months in the triplet group and 9.43 months in the doublet group.

Sources:

  • Evaluating First-line Chemotherapy Regimens and Platinum Choices in HER2-Negative Metastatic Gastric Cancer: A Retrospective Analysis. Journal of Oncological Sciences, 2025, 11(2):134-144. (Journal of Oncological Sciences - https://www.journals.elsevier.com/journal-of-oncological-sciences).
  • The publisher for Journal of Oncological Sciences is Galenos Publishing House.
  • A free version of this journal article is available at https://doi-org.sdpl.idm.oclc.org/10.37047/jos.galenos.2025.2025-6-2.

Read more